I think I can answer the question, because in most of the university centres across Canada, we have been evaluating disease processes for the last 20 years. We did this with coronary artery angioplasty and with peripheral arterial angioplasty. We've done it with carotid disease. We're doing it with the discovery of whether or not carotid angioplasty is better than surgery. So we have tremendous expertise across the country in evaluating and monitoring the efficacy of novel and new treatments for all disease processes.
So I don't think it's an issue of how our ethics committees would be structured to oversee the process of intervention of the venous lesions described by Dr. Zamboni. I think we have tremendous talent across the country to do that--and within the academic centres.